More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$495401421
EPS
-0.79
P/E ratio
--
Price to sales
1.49
Dividend yield
--
Beta
0.29476
Previous close
$11.87
Today's open
$11.96
Day's range
$11.62 - $12.01
52 week range
$9.39 - $16.29
CEO
Eric Honroth
Employees
632
Headquarters
Latham, NY
Exchange
Nasdaq Global Select
Shares outstanding
42054450
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO's strong NanoKnife sales, expanding Med Tech portfolio and solid fiscal Q1 results support growth prospects, despite tariff and inflation pressures.
Zacks Investment Research • Nov 13, 2026

AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the grant of inducement awards to Eric Honroth in connection with his appointment as Chief Executive Officer of the Company effective as of November 2, 2026. On November 2, 2026 (the “Grant Date”), as an inducement.
Business Wire • Nov 6, 2026

AngioDynamics to Participate in Upcoming Investor Conferences
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management is scheduled to participate in the following upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Monday, November 9, 2026, from 8:00-8:35 AM ET Canaccord Genuity's MedT.
Business Wire • Oct 29, 2026

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in.
Business Wire • Oct 21, 2026

AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist
AngioDynamics, Inc. remains a volatile small-cap med-tech, with promising growth drivers but inconsistent execution and margin trajectory. ANGO's AlphaVac, Auryon, and NanoKnife are gaining traction, yet face entrenched competitors and unpredictable clinician adoption, especially for NanoKnife. Recent results showed strong Med Tech growth and margin improvement, but higher-than-expected operating expenses and NanoKnife volatility spooked investors.
Seeking Alpha • Oct 15, 2026

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation tec.
Business Wire • Oct 14, 2026

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
Zacks Investment Research • Oct 9, 2026

Why AngioDynamics Crashed Today
AngioDynamics beat on both top and bottom lines this morning. The company still lost $0.04 per share, pro forma, and its GAAP loss was four times bigger.
The Motley Fool • Oct 8, 2026

AngioDynamics Q1 Earnings Call Highlights
AngioDynamics NASDAQ: ANGO reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year outlook and announced that Eric Honroth will become president and chief executive officer effective Nov. 2.
MarketBeat • Oct 8, 2026

AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
Seeking Alpha • Oct 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell AngioDynamics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.